Anemia

Healio spoke with Jay B. Wish, MD, about unmet needs in the management of anemia.

Healio spoke with Jay B. Wish, MD, about managing anemia in patients on dialysis.

Healio spoke with Jay B. Wish, MD, about treatment approaches in patients with CKD and anemia.

Healio spoke with Jay B. Wish, MD, about managing challenging cases of anemia.

Healio spoke with Jay B. Wish, MD, about new developments in anemia care.

Akebia Therapeutics Inc. has resubmitted its new drug application to the FDA for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in adults on dialysis.

While clinical trials have shown hypoxia-inducible factor prolyl hydroxylase inhibitors to be non-inferior to other anemia drugs, questions remain about IV or oral iron supplementation and inflammation, according to a new report.

The FDA approved momelotinib for treatment of patients with myelofibrosis and anemia regardless of prior myelofibrosis therapy.

Providing iron supplements during prenatal visits improved hematocrit levels and anemia rates and reduced transfusions for acute blood loss anemia among women with Medicaid insurance, researchers reported.

The FDA approved luspatercept-aamt as first-line treatment for anemia among certain adults with myelodysplastic syndrome.